Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
206.4 USD | +1.96% | +5.86% | -20.48% |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.